预约演示
Sanofi’s amlitelimab shows best-in-class response in atopic dermatitis
临床3期临床结果引进/卖出
Sanofi’s investigational drug amlitelimab is forecast to generate $581m in sales by 2030, as per GlobalData analysis. Credit: Golden Shrimp via Shutterstock.
Sanofi has announced encouragiamlitelimab from the second part of a study with the OX40 antibody amlitelimab, which showed sustained improvement in treating moderate to severe atopic dermatitis symptoms in previously treated patients.
Sanofi second part of the STREAM-AD study, patients initially responding to amlitelOX40 antibodyramlitelimabo either continue treatment or withdraw over 28 weeks. Those continuatopic dermatitisntained high responder rates for Eczema Area and Severity Index (EASI-75) and/or Investigator Global Assessment (IGA 0/1), as did those withdrawn from treatment – 69.2% of patients continued IGA 0/1 and/or EASI-75 response compared to 58.8% in those who had withdrawn.
A pooled analysis showed that those who continued treatment maintained an IGamlitelimabnse in 71.9% compared to 57% in the treatment-withdrawn group, with EASI-75 response maintained in 69% compared to 61.6% of patients, respeEczemay. Atopic dermatitis-related biomarkers remained reduced at week 52 in both groups, highlighting durable control of the condition post-amlitelimab withdrawal.
Results from this part of the study indicate amlitelimab’s potential for durable off-drug efficacy, which means less frequent dosing every 12 weeks could be evaluated, explained chair of the department of dermatology and allergy at theAtopic dermatitistal Schleswig-Holstein Stephan Weidinger, in the 11 March press release.amlitelimab
The 12-week dosing schedule of amlitelimab 25amlitelimab500mg loading dose is now being investigated in a larger Phase III clinical program (OCEANA).University Hospital Schleswig-Holstein
See Also:amlitelimab
AD/PD 2024: BioVie’s novel NE3107 shows promise but confirmatory trial needed
GlobalData is the parent company of Clinical Trials Arena.
Amlitelimab0 inhibitoanti-OX40 ligand monoclonal antibodyAmgen and Kyowa Kirin’s KHK4083 (rocatinlimaatopic dermatitisndhidradenitis suppurativaodasthma, alopecia areataorceliac disease marksystemic sclerosisan. KHK4083 is forecast to generate $960m in 2029, according to GlobalData.
In October 2023, Astria Therapeutics signed an exclusive global agreement to license Ichnos Sciences’ OX40 portfolio to treat atopic dermatitis in a $305m deal, paying $15m upfront. The portfolio includes monoclonal antibody OX40 antagonists STAR-0310 and telazorlimab.
Atopic dOX40 inhibitorOX40titis is a long-teatopic dermatitisf eczema cAmgenly seKyowa Kirine wKHK4083 (rocatinlimab) a malfAmgenoning immune system.KHK4083
In the announcemeAstria Therapeutics data, the head of global development, immunologyIchnos SciencesonOX40Sanofi, Naimish Pateatopic dermatitisrecedented to see this type of durability of clinical response, which we believe cOX40 be very meanSTAR-0310 patitelazorlimabthe reason why we selected an every 12-week dosing regimen in the AD pivotal programme.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。